Who is on it, and how far along Every drug ChEMBL records acting on ALK, by the furthest stage it has reached for any use, coloured by modality.
How to read this Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
Approved4 Alectinib Alectinib SponsorRoche ModalitySmall molecule ActionInhibitor Open trials44 Lorlatinib Lorlatinib SponsorPfizer ModalitySmall molecule ActionInhibitor Open trials42 Crizotinib Crizotinib SponsorPfizer ModalitySmall molecule ActionInhibitor Open trials39 Ceritinib Ceritinib SponsorNovartis Pharmaceuticals ModalitySmall molecule ActionInhibitor Open trials11 Phase 11 PLB1003 PLB1003 SponsorBeijing Pearl Biotechnology Limited Liability Company ModalityOther ActionInhibitor Open trials0
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: EML4-ALK inhibitor. The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 29 in all, from ClinicalTrials.gov. Trial Drug Phase Status Lead sponsor First posted Lorlatinib Plus TNG462 in ALK+ MTAP Del NSCLC Lorlatinib Phase 1 Not yet recruiting Dana-Farber Cancer Institute Nov 16, 2026 Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric Glioma Alectinib Phase 2 Not yet recruiting St. Jude Children's Research Hospital Nov 4, 2026 Ceritinib Treatment for Recurrent Meningiomas Ceritinib Phase 2 Not yet recruiting Kevin Petrecca Oct 23, 2026 Master Protocol for Basket Clinical Trials of Targeted Therapies Based on Proteome and Whole Exome Sequencing Screening in Patients With Advanced Solid Tumors Crizotinib Not applicable Active, not recruiting National Cancer Center, Korea Oct 23, 2026 Perioperative Targeted Therapy in Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer With Rare Driver Mutations Alectinib Phase 2 Not yet recruiting Shanghai Zhongshan Hospital Sep 21, 2026 TailorDose Lung: Decentralized TDM of Taxanes and ALK Inhibitors Using Capillary Self-Sampling Alectinib, Lorlatinib Not applicable Not yet recruiting Karolinska Institutet Sep 16, 2026 A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer Crizotinib Phase 3 Not yet recruiting Guangzhou JOYO Pharma Co., Ltd Sep 11, 2026 Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma Crizotinib Phase 3 Recruiting IDEAYA Biosciences Sep 4, 2026 Molecularly Tailored Therapy in Advanced Pancreatic Cancer Crizotinib Phase 2 Not yet recruiting Herlev Hospital Sep 3, 2026 Study of NXP900 With Lorlatinib in ALK+ Lung Cancer Lorlatinib Phase 1 Recruiting Nuvectis Pharma, Inc. Aug 25, 2026 Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib Lorlatinib Phase 1 Recruiting University of Chicago Aug 24, 2026 A Multicenter Exploratory Clinical Study of Iruplaltinib Combined With Pemetrexed as Neoadjuvant Therapy for Resectable ALK-Positive Non-Squamous Non-Small Cell Lung Cancer Alectinib Phase 2 Not yet recruiting First Affiliated Hospital of Fujian Medical University Aug 18, 2026 Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLC Lorlatinib Phase 2 Not yet recruiting Guangdong Association of Clinical Trials Aug 6, 2026 Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / Mixed Lorlatinib Phase 4 Not yet recruiting Hunan Cancer Hospital Jun 29, 2026 Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC Lorlatinib — Not yet recruiting Sun Yat-sen University Jun 29, 2026 Efficacy and Safety of Ensartinib Combined With Anlotinib in Lorlatinib-Resistant ALK-Positive NSCLC Lorlatinib Phase 4 Not yet recruiting Qiming Wang Jun 26, 2026 OBSERVE: A Pilot Study Of Omission Of Brain Metastasis Stereotactic Radiosurgery Following Resection With CNS-Active Systemic Therapy Alectinib Phase 1 Recruiting M.D. Anderson Cancer Center Jun 18, 2026 Multidisciplinary Treatment of Stage III ALK+ NSCLC With Neoadjuvant Alectinib and Chemotherapy Alectinib Phase 2 Not yet recruiting Wen-zhao ZHONG May 7, 2026 Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa) Alectinib, Crizotinib Phase 1 / Phase 2 Not yet recruiting China Medical University Hospital May 1, 2026 A Clinical Study to Evaluate the Pharmacokinetics and Safety of Anecatibin Fumarate Capsules in Subjects With Impaired Liver Function Versus Normal Liver Function Crizotinib Phase 1 Not yet recruiting Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Apr 20, 2026 Multi Omics Molecular Characteristics and Immunophenotyping of Lung Signet Ring Cell Carcinoma Alectinib, Crizotinib — Recruiting First People's Hospital of Hangzhou Oct 3, 2025 Using Tumor Models to Determine Treatments Ceritinib Phase 2 Recruiting University Health Network, Toronto Feb 6, 2025 Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLC Crizotinib — Not yet recruiting National Cancer Center, China Nov 19, 2024 Antineoplastic Drugs in Elderly Patients Ceritinib — Recruiting Shandong University Jul 20, 2022 A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) Ceritinib Phase 1 / Phase 2 Recruiting Nuvalent Inc. May 20, 2022 Improving Public Cancer Care by Implementing Precision Medicine in Norway Ceritinib Phase 2 Recruiting Oslo University Hospital Mar 26, 2021 Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation Ceritinib Phase 2 Recruiting Hunan Province Tumor Hospital Mar 26, 2020 Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC Ceritinib Phase 1 Active, not recruiting H. Lee Moffitt Cancer Center and Research Institute Aug 2, 2018 Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study Ceritinib Phase 4 Active, not recruiting Novartis Pharmaceuticals Oct 23, 2015
Show all 29Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3883330 , ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov , checked daily; this page as of 2026-11-21. ChEMBL and Open Targets